Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy L Apetoh, F Ghiringhelli, A Tesniere, M Obeid, C Ortiz, A Criollo, G Mignot, ... Nature medicine 13 (9), 1050-1059, 2007 | 3340 | 2007 |
Calreticulin exposure dictates the immunogenicity of cancer cell death M Obeid, A Tesniere, F Ghiringhelli, GM Fimia, L Apetoh, JL Perfettini, ... Nature medicine 13 (1), 54-61, 2007 | 3224 | 2007 |
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death N Casares, MO Pequignot, A Tesniere, F Ghiringhelli, S Roux, N Chaput, ... The Journal of experimental medicine 202 (12), 1691-1701, 2005 | 1573 | 2005 |
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance F Martins, L Sofiya, GP Sykiotis, F Lamine, M Maillard, M Fraga, ... Nature reviews Clinical oncology 16 (9), 563-580, 2019 | 1530 | 2019 |
Calreticulin exposure is required for the immunogenicity of γ-irradiation and UVC light-induced apoptosis M Obeid, T Panaretakis, N Joza, R Tufi, A Tesniere, P Van Endert, ... Cell Death & Differentiation 14 (10), 1848-1850, 2007 | 555 | 2007 |
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ J Haanen, M Obeid, L Spain, F Carbonnel, Y Wang, C Robert, AR Lyon, ... Annals of Oncology 33 (12), 1217-1238, 2022 | 275 | 2022 |
Ecto‐calreticulin in immunogenic chemotherapy M Obeid, A Tesniere, T Panaretakis, R Tufi, N Joza, P Van Endert, ... Immunological reviews 220 (1), 22-34, 2007 | 252 | 2007 |
Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from “silent” to immunogenic M Obeid, T Panaretakis, A Tesniere, N Joza, R Tufi, L Apetoh, ... Cancer research 67 (17), 7941-7944, 2007 | 202 | 2007 |
New therapeutic perspectives to manage refractory immune checkpoint-related toxicities F Martins, GP Sykiotis, M Maillard, M Fraga, C Ribi, T Kuntzer, O Michielin, ... The Lancet Oncology 20 (1), e54-e64, 2019 | 175 | 2019 |
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy J Haanen, MS Ernstoff, Y Wang, AM Menzies, I Puzanov, P Grivas, ... Annals of Oncology 31 (6), 724-744, 2020 | 160 | 2020 |
ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin M Obeid The journal of Immunology 181 (4), 2533-2543, 2008 | 138 | 2008 |
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy J Haanen, M Ernstoff, Y Wang, A Menzies, I Puzanov, P Grivas, J Larkin, ... Journal for immunotherapy of cancer 8 (1), 2020 | 113 | 2020 |
Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference N Chaput, S De Botton, M Obeid, L Apetoh, F Ghiringhelli, T Panaretakis, ... Journal of molecular medicine 85, 1069-1076, 2007 | 100 | 2007 |
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy E Ghisoni, A Wicky, H Bouchaab, M Imbimbo, J Delyon, BG Moura, ... European Journal of Cancer 149, 153-164, 2021 | 98 | 2021 |
Reactivation of IgA vasculitis after COVID-19 vaccination M Obeid, C Fenwick, G Pantaleo The Lancet Rheumatology 3 (9), e617, 2021 | 73 | 2021 |
COVID-19 and lung cancer: risks, mechanisms and treatment interactions A Addeo, M Obeid, A Friedlaender Journal for immunotherapy of cancer 8 (1), 2020 | 71 | 2020 |
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study F Zou, D Faleck, A Thomas, J Harris, D Satish, X Wang, A Charabaty, ... Journal for immunotherapy of cancer 9 (11), 2021 | 61 | 2021 |
A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy A Horisberger, S La Rosa, JP Zurcher, S Zimmermann, F Spertini, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 60 | 2018 |
Humoral responses against variants of concern by COVID-19 mRNA vaccines in immunocompromised patients M Obeid, M Suffiotti, C Pellaton, H Bouchaab, A Cairoli, V Salvadé, ... JAMA oncology 8 (5), e220446-e220446, 2022 | 55 | 2022 |
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis J Doms, JO Prior, S Peters, M Obeid Annals of Oncology 31 (9), 1273-1275, 2020 | 46 | 2020 |